The identification of these phosphoproteins as biomarkers of the PI3K-AKT-mTOR pathway inhibitors would therefore enable the determination of the efficacy of these inhibitors in PI3K pathway (and therefore breast cancer) inhibition, based on the level of phosphorylation of these biomarkers. The gene discussed is AKT1; the disease is breast cancer.